Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $19.0 million.

  • Avidity Biosciences' Share-based Compensation rose 3499.86% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 4572.73%. This contributed to the annual value of $51.4 million for FY2024, which is 3438.07% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Share-based Compensation is $19.0 million, which was up 3499.86% from $17.7 million recorded in Q2 2025.
  • Avidity Biosciences' Share-based Compensation's 5-year high stood at $19.0 million during Q3 2025, with a 5-year trough of $3.7 million in Q1 2021.
  • Its 5-year average for Share-based Compensation is $9.9 million, with a median of $9.5 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 72427.62% in 2021, then skyrocketed by 1320.3% in 2024.
  • Over the past 5 years, Avidity Biosciences' Share-based Compensation (Quarter) stood at $4.5 million in 2021, then surged by 61.8% to $7.3 million in 2022, then soared by 34.73% to $9.8 million in 2023, then surged by 43.76% to $14.2 million in 2024, then surged by 34.42% to $19.0 million in 2025.
  • Its Share-based Compensation was $19.0 million in Q3 2025, compared to $17.7 million in Q2 2025 and $17.7 million in Q1 2025.